Nanopore-based DNA Sequencing Technology to Diagnose Genetic Disorder Huntington's Disease
The world has witnessed a groundbreaking advancement in genetic disorder diagnostics with the development of nanopore-based DNA sequencing technology specifically tailored for Huntington's Disease.
At the forefront of this breakthrough is the MinION, a compact handheld device that deciphers individual DNA strands through the generation of electronic signals as the DNA traverses nanopores within a membrane.
In real-time, this technology enables the identification of sequence variations, which can then be compared to a database of known genetic sequences to detect the presence of the Huntington's Disease genetic disorder.
Compared to conventional testing methods, the MinION DNA sequencing devices yield significantly faster results, eliminating the need for subsequent analysis of DNA segments and reducing waiting times.
To ensure its clinical viability, the technology must adhere to stringent quality control standards, providing reliable results for every sample examined.
Huntington's disease, an inherited neurodegenerative disorder, impairs the proper functioning of specific regions in the brain, with symptoms progressively worsening over time. Typically, the disease proves fatal within a span of 20 years.
At present, individuals with symptoms of Huntington’s Disease have a blood test and then wait up to two weeks for the result.
